February 24, 2024
Loading...
You are here:  Home  >  Health Care & Life Science  >  Current Article

FTC blocks Amgen’s $28B Horizon deal

IN THIS ARTICLE

Amgen's new research and development facility in San Francisco. (courtesy photo) Amgen’s desire to land its next blockbuster drug — or two — has been put on hold. The Federal Trade Commission sued Amgen in an effort to block the company’s proposed acquisition of Horizon Therapeutics for nearly $28 billion, citing concerns that it would…

Subscribe

    This article is only available to Business Times subscribers
  • Subscribers: or REGISTER for complete digital access.
  • Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
  • Check the STATUS of your Subscription Account.